Acute Infective Polyneuritis

Bradford, John Rose; Bashford, E. F.; Wilson, Jeffrey A.

doi:10.1097/00005053-192011000-00020

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time as Guillain and Barre described their patients, others reported, independently, identical cases occurring among British soldiers. These were given different names such as "infective polyneuritis" [85], "acute ascending paralysis" [22], "acute infective polyneuritis" [13] and "acute febrile neuritis" [68]. Thus, for many years, many different names were used for the same syndrome.…”

Section: Chapter 1 the Guillain -Barre Syndrome: An Introduction 11 mentioning

confidence: 99%

Treatment of the Guillain-Barré Syndrome

Kleyweg¹,

Meché

1990

Intensivmedizinisches Seminar

View full text Add to dashboard Cite

Section: Chapter 1 the Guillain -Barre Syndrome: An Introduction 11 mentioning

confidence: 99%

Treatment of the Guillain-Barré Syndrome

Kleyweg¹,

Meché

1990

Intensivmedizinisches Seminar

View full text Add to dashboard Cite

“…P1 is analogous to th CNS myelin basic protein with a molecular mass of 18500Da. P2 protein is comprised of 131 amino acids and has a molecular weight of 14 500 Da [7]. It is the major protein responsible for the induction of EAN.…”

Section: Peripheral Nervous System Structure and Antigenesmentioning

confidence: 99%

“…Indeed, for some time the disorder was called acute infective polyneuritis [7]. A herpes virus of birds, known as Marek's disease virus, produces a lymphoproliferative disorder in chickens.…”

Section: Etiology and Pathogenesismentioning

confidence: 99%

Guillain-Barr� syndrome: clinical and immunological aspects

Rostami¹

1995

Springer Semin Immunopathol

View full text Add to dashboard Cite

Immune-mediated PNS disorders comprise a significant segment of diseases of the nervous system. Studies on GBS as a prototype of these disorders and its experimental model EAN have helped to elucidate some of the mechanisms responsible for myelin injury in the PNS. These mechanisms, although partially understood have been useful in implementing therapies such as plasmapheresis and IVIG and various other immunomodulators. The question of whether an infectious agent such as a virus can directly damage the myelin sheath and/or Schwann cells or whether the agent triggers an immune response against self through antigenic mimicry remains unanswered. The association between C. jejuni infection and GBS has opened new areas of investigation in understanding the immunopathogenesis of the disease. Similar observations with other environmental factors may be made in the future, pointing to the possibility that GBS may not be caused by a single agent but could be the result of an immunological attack on the PNS myelin assembly by a variety of agents or factors. Regardless of the etiology, if the myelin injury is aggravated by product of the immune cells, such as various cytokines, neutralization of these factors could help lessen the burden of injury to the nerves. Future research in autoimmune disorders of the PNS needs to focus on identifying environmental factors that directly, or indirectly through antigen mimicry, damage the PNS myelin. In parallel, further understanding of the immunopathogenesis by dissecting the immunological phenomenon at the systemic and local levels, especially the role of cytokines, growth factors, and adhesion molecules will pave the way for more rational therapies, even if the causative factors are not known. Studies in laboratory animals have demonstrated the efficacy of selective immunotherapy through modulation of the trimolecular complex, i.e., T cell receptor, MHC/molecule, and antigen. Immunological tolerance, presumably through deletion of autoreactive clones, clonal anergy, or active suppression, has proven effective in animals. Other modes of immunotherapy such as nonspecific depletion of T or B cells or down-regulation of activated cells have also been shown to abolish or decrease the severity of experimental autoimmune neurological disorders, including EAN. These immunotherapeutic modalities may become applicable to human autoimmune neuropathies.

show abstract

Acute Infective Polyneuritis

Cited by 2 publications

References 0 publications

Treatment of the Guillain-Barré Syndrome

Treatment of the Guillain-Barré Syndrome

Guillain-Barr� syndrome: clinical and immunological aspects

Contact Info

Product

Resources

About